During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the AML Hub spoke to Norbert Vey, Institut Paoli-Calmettes, Marseille, FR. We asked, What challenges arise in the management of AML in complete remission?
Recent improvements in induction chemotherapy have resulted in 70–80% of patients reaching complete remission, however, the majority will eventually relapse. In this video, Vey discusses the challenges and corresponding solutions in managing relapse, including:
• patient-related factors, such as age, cytogenetics, secondary AML, and minimal residual disease
• targeted therapies, such as venetoclax, as an alternative to standard consolidation
• maintenance strategies, combining different agents for elderly patients with AML
